ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- icotec ag, the leading company in the field of innovative spinal tumor implants is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners ('MVM'), a global healthcare venture capital firm.

瑞士ALTSTAETTEN和康涅狄格州东哈特福德，2024年1月24日，创新脊柱肿瘤植入物领域的领先公司icotec ag很高兴宣布，通过与全球医疗风险投资公司MVM Partners（“MVM”）建立战略伙伴关系，这是其成长历程中的一个重要里程碑。

icotec is commercializing groundbreaking BlackArmor® Carbon/PEEK products that may offer significant clinical advantages over traditional metal implants in the context of spine oncology, making the full potential of the treatment possibilities available for patients along their journey..

icotec正在将开创性的BlackArmor®碳/聚醚醚酮产品商业化，与传统金属植入物相比，该产品在脊柱肿瘤学方面可能具有显着的临床优势，使患者在旅途中充分发挥治疗潜力。。

Since receiving FDA clearance in 2019, many designated US cancer centers have adopted icotec's BlackArmor® products. This investment will enable icotec to continue its impressive growth and strengthen its research and development capabilities to expand the portfolio into the underserved indications of spinal infection and osteoporosis..

自2019年获得FDA批准以来，许多指定的美国癌症中心已经采用了icotec的BlackArmor®产品。这项投资将使icotec继续其令人印象深刻的增长，并加强其研发能力，将投资组合扩展到脊柱感染和骨质疏松症的服务不足适应症。。

'We are thrilled to partner with MVM, whose deep understanding of the healthcare landscape aligns seamlessly with our vision for the future,' said Roger Stadler, Group CEO of icotec ag. 'This partnership marks a pivotal moment for icotec, supporting us to advance our mission of improving patient outcomes by offering a convincing alternative to the 100-year-old material technology of metal implants.'.

icotec ag集团首席执行官罗杰·施塔德勒（Roger Stadler）说：“我们很高兴与MVM合作，MVM对医疗保健领域的深刻理解与我们对未来的愿景无缝结合。这一合作关系标志着icotec的关键时刻，通过提供一种令人信服的替代金属植入物100年历史的材料技术，支持我们推进改善患者预后的使命。”。

MVM has a strong track record of supporting and partnering with innovative healthcare companies and recognizes the potential of icotec's technology to transform patient care. The partnership represents a vote of confidence in icotec's leadership, products, and the overall trajectory of the company.

MVM在支持和合作创新医疗保健公司方面有着良好的记录，并认识到icotec技术在改变患者护理方面的潜力。该合作关系代表了对icotec领导、产品和公司整体发展轨迹的信任投票。

'We are excited to support icotec in its mission to revolutionize the spinal implant industry,' commented Thomas Casdagli, Partner at MVM. 'icotec's BlackArmor® Carbon/PEEK implants represent a huge step forward in the treatment of complex spine disease. For the first time clinicians have the choice to be able to accurately visualize and treat patients after surgery without the artifacts and limitations of traditional metal implants.

MVM合伙人托马斯·卡斯达利（ThomasCasdagli）评论道：“我们很高兴支持icotec彻底改变脊柱植入行业的使命。”icotec的BlackArmor®碳/PEEK植入物代表了治疗复杂脊柱疾病的巨大进步。临床医生首次可以选择在手术后准确地观察和治疗患者，而不需要传统金属植入物的伪影和局限性。

We see this as a big step forward for patient care. We look forward to working closely with the icotec team to drive continued success and growth.'.

我们认为这是患者护理向前迈出的一大步。我们期待着与icotec团队密切合作，以推动持续的成功和增长。”。

WISTAMA Finanz- und Beteiligungs AG, the family office of the Stadler family that founded icotec, remains fully invested as majority shareholder and committed to the long-term development of icotec.

WISTAMA Finanz-und Beteiligungs AG是成立icotec的Stadler家族的家族理财办公室，仍然作为大股东进行充分投资，并致力于icotec的长期发展。

For media inquiries or further information, please contact:

有关媒体查询或更多信息，请联系：

Remo Keller, Group CFO, [email protected], +41 71 757 00 96

集团首席财务官Remo Keller，[受电子邮件保护]，+41 71 757 00 96

About icotec ag

关于icotec ag

icotec is the leading company for the treatment of spinal tumors with a new generation of high-tech implants. With its BlackArmor® Carbon/PEEK implants, icotec combines cutting-edge technologies and industry expertise to deliver innovative and reliable solutions for spine surgeons and their patients and is dedicated to advancing the field of spinal implantation.

icotec是使用新一代高科技植入物治疗脊柱肿瘤的领先公司。凭借其BlackArmor®碳/聚醚醚酮植入物，icotec将尖端技术和行业专业知识相结合，为脊柱外科医生及其患者提供创新可靠的解决方案，并致力于推进脊柱植入领域。

With a track record of clinical success and a commitment to continuous innovation, icotec is poised to shape the future of spinal surgery. The comprehensive product portfolio has received FDA approval and is supported by numerous Key Opinion Leaders and Cancer Therapy Centers worldwide. More information can be found at www.icotec-medical.com..

凭借临床成功的记录和不断创新的承诺，icotec有望塑造脊柱外科的未来。该综合产品组合已获得FDA批准，并得到全球众多关键意见领袖和癌症治疗中心的支持。有关更多信息，请访问www.icotec-medical.com。。

About MVM Partners

关于MVM合作伙伴

MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston and London, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com..

自1997年以来，MVM一直投资于高增长的医疗保健业务。MVM拥有波士顿和伦敦的团队，拥有广泛的全球投资前景，涵盖医疗技术、制药、诊断、合同研究和制造、数字健康和其他医疗保健领域。有关更多信息，请访问www.mvm.com。。

SOURCE icotec ag

来源：icotec ag